PURPOSES: Despite many recent reports on the effects of trastuzumab for @entity0 , many problems remain regarding combination drug treatment and its significance. We report our experience with @entity0 @entity1 who received combination therapy with trastuzumab+ @entity1311 . SUBJECTS AND METHOD: Three @entity1 with @entity1 @entity1722 ( @entity1722 )-positive @entity0 were the subjects. Combination therapy with trastuzumab and @entity1311 was carried out as a primary therapy, and its therapeutic effects were evaluated based on image findings, @entity5 markers and observation of resected specimens. RESULTS: The @entity5 in the three @entity1 were all clinically complete response (cCR). Those in two surgically treated @entity1 were near pathologically complete response (pCR), ie, a small amount of @entity5 cells remained in the galactophore, whereas the histological therapeutic effect was Grade 2b. In two @entity1 with liver metastases, the metastatic @entity5 disappeared on the image after the therapy. In two @entity1 whose @entity5 marker was increased at the first examination, the level of increase was markedly lowered by the therapy. Neither infusion reaction nor heart functional impairment was found in any of the three @entity1 . CONCLUSIONS: For @entity1 with @entity0 , a regimen containing trastuzumab would produce significant therapeutic effects if the @entity5 is @entity1722 -positive. The regimen would also contribute to the prognosis of such @entity1 since it might produce pCR. Since the risk of severe adverse effects is low and the treatment with trastuzumab can be conducted safely as an ambulatory treatment, high @entity1 QOL seems possible. These findings suggest that combination therapy with trastuzumab+ @entity1311 is effective as a primary therapy for @entity1722 -positive @entity0 .

[Combination treatment with trastuzumab and @entity1311 as primary therapy for XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'human', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'advanced breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1722 :: ('2064', 'Gene') :: ['epidermal growth factor receptor 2', 'HER2']
@entity0 :: (MESH:D001943,Disease) :: ['advanced breast cancer']
